Cover Image
市場調查報告書

前庭病變的開發中產品分析

Vestibular Diseases - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 302492
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
前庭病變的開發中產品分析 Vestibular Diseases - Pipeline Review, H2 2014
出版日期: 2014年11月18日 內容資訊: 英文 26 Pages
簡介

所謂前庭病變,是指前庭神經疾病或損傷造成的傷害。因遺傳性或環境性因素發病並惡化,也會因不特定理由發病。主要症狀有旋轉性、不平衡性暈眩、協調運動障礙、肌肉痛、關節痛、聽覺損失障礙或重聽、焦慮症、恐慌、憂鬱等。主要治療藥有Benzodiazepine和類固醇,抗病毒藥物,抗生素等。

本報告提供全球各國治療前庭病變用的開發中產品開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再彙整主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

前庭病變概要

治療藥的開發

  • 前庭病變開發中產品:概要
  • 前庭病變開發中產品:比較分析

各企業開發中的前庭病變治療藥

開發中產品的概要

  • 初期階段的產品

前庭病變治療藥:開發中的產品的一覽(各企業)

前庭病變治療藥的開發企業

  • Quark Pharmaceuticals, Inc.
  • Griffin Discoveries BV
  • Sensorion Pharmaceuticals

前庭病變:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 分子類別

藥物簡介

  • 中樞神經系統(CNS)siRNA
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • SR-1001
  • 阻礙組織胺H4受體用小分子
  • SR-2001
  • SENS-300系列
  • SENS-100系列
  • SENS-200系列

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5734IDB

Summary

Global Markets Direct's, 'Vestibular Diseases - Pipeline Review, H2 2014', provides an overview of the Vestibular Diseases's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vestibular Diseases, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vestibular Diseases and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Vestibular Diseases
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Vestibular Diseases and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Vestibular Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Vestibular Diseases pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Vestibular Diseases
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Vestibular Diseases pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vestibular Diseases Overview
  • Therapeutics Development
    • Pipeline Products for Vestibular Diseases - Overview
    • Pipeline Products for Vestibular Diseases - Comparative Analysis
  • Vestibular Diseases - Therapeutics under Development by Companies
  • Vestibular Diseases - Pipeline Products Glance
    • Early Stage Products
  • Vestibular Diseases - Products under Development by Companies
  • Vestibular Diseases - Companies Involved in Therapeutics Development
    • Griffin Discoveries BV
    • Quark Pharmaceuticals, Inc.
    • Sensorion S.A.S.
  • Vestibular Diseases - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Drug Profiles
    • SENS-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SENS-200 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SENS-300 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • siRNA for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vestibular Diseases - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vestibular Diseases, H2 2014
  • Number of Products under Development for Vestibular Diseases - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Vestibular Diseases - Pipeline by Griffin Discoveries BV, H2 2014
  • Vestibular Diseases - Pipeline by Quark Pharmaceuticals, Inc., H2 2014
  • Vestibular Diseases - Pipeline by Sensorion S.A.S., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Vestibular Diseases - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Vestibular Diseases, H2 2014
  • Number of Products under Development for Vestibular Diseases - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top